Allergy, Asthma and Immunology - nuevo mensaje

Skip to first unread message

May 26, 2024, 7:54:34 AMMay 26

Allergy, Asthma and Immunology
The Multiple Trajectories of the Allergic March.
por May 25, 2024


de Las Vecillas L, Quirce S.  J Investig Allergol Clin Immunol. 2024 Apr 12;34(2):75-84. doi: 10.18176/jiaci.0983.


Etiologic features and risk factors related to the development of the allergic march and preventive
interventions to impact its course. TH2 indicates type 2 helper T cell; AIT, allergen immunotherapy
The allergic march comprises the sequential appearance of a series of allergic comorbidities. However, variability in the onset and progression of allergic diseases generates a heterogeneous scenario that does not follow a linear and single trajectory.

Almost half of the pediatric population presents at least 1 allergy symptom. However, only 4%-6% present multimorbidity, with several allergic diseases co-occurring. It has recently been shown that although they share etiological mechanisms and risk factors, allergic diseases arise independently. In most cases, progression is not consecutive, or at least not the same in all patients...

Continuar Leyendo
AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial
por May 25, 2024

Becker S, Deshmukh S, De Looze F, et al. Allergy. 2024; 00: 1-10. doi:10.1111/all.16116



Saline nasal sprays are frequently used in the management of seasonal allergic rhinitis (SAR) for the cleansing and clearing of aeroallergens from the nasal cavity. Also using a drug-free approach, AM-301 nasal spray is forming a thin film barrier on the nasal mucosa to prevent contact with allergens, trap them, and facilitate their discharge. A clinical trial compared the efficacy, safety, and tolerability of AM-301 and saline spray in SAR.


A total of 100 patients were randomized 1:1 to self-administer AM-301 or saline 3 × daily for 2 weeks. Primary efficacy endpoint: reduction in mean daily reflective Total Nasal Symptom Score (rTNSS). Secondary efficacy endpoints: reduction in mean instantaneous TNSS and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), global impression of efficacy.

Safety and tolerability: adverse events, relief medication use, symptom-free days, global impression of tolerability.


Global impression of efficacy and tolerability by subjects and investigators. 

AM-301-treated patients achieved a significantly lower rTNSS than the saline group (LS square means difference −1.1, 95% CI −1.959 to −0.241, p = .013) with improvement observed across all individual nasal symptoms...

Continuar Leyendo

Reply all
Reply to author
0 new messages